glp-1 gip medications muscle loss comparison Compare Options | Ozempic v Mounjaro | WeightWatchers Dietary intake by patients taking
Description
These blockbuster therapies are clear indicators of where innovation and market momentum are heading in 2025
Lighter belly, healthier gut
In order to better understand the full scope of the access challenges across the US for these critical medications, we launched the GLP-1 Supply Tracker so that anyone can be a part of advocating for continued access to the medications they need.
Background Guidelines recommend combination therapy with glucagonlike peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) for cardiorenal risk reduction in people with type 2 diabetes (T2D)
